AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29490289 — intervention group
Group type: EXPERIMENTAL
Intervention: OC + DHEA
Number of subjects: 81
Study 29490289 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA co-administration
Number of subjects: 81
Study 26952317 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysozyme hydrochloride (LYS)
Number of subjects: 48
Study 26952317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 23888869 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally synchronized audio-visual components
Number of subjects: 120
Study 23888869 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporally desynchronized audio-visual components (366, 500, or 666 ms)
Number of subjects: 120
Study 22261795 — intervention group
Group type: EXPERIMENTAL
Intervention: C-MAC video laryngoscope
Number of subjects: 300
Study 22261795 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 300
Study 21180218 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg intravaginally)
Number of subjects: 66
Study 21180218 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone (0.5 mg intracervically)
Number of subjects: 66
Study 17585117 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human [rDNA Origin] insulin
Number of subjects: 0
Study 15172365 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC‐001 (0.8 g MnCl2)
Number of subjects: 12
Study 15172365 — intervention group
Group type: EXPERIMENTAL
Intervention: CMC‐001 (1.6 g MnCl2)
Number of subjects: 12
Study 12231595 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 66
Study 12231595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9655270 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefazolin intravenously every 8 hours
Number of subjects: 139
Study 9655270 — intervention group
Group type: COMPARATOR
Intervention: Placebo intravenously every 8 hours
Number of subjects: 139
Study 7815722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 80
Study 7815722 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 80
Study 7815722 — intervention group
Group type: EXPERIMENTAL
Intervention: Drip Infusion Cholecystography (DIC)
Number of subjects: 80
Study 2673337 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated external cephalic version
Number of subjects: 180
Study 2673337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no version attempted)
Number of subjects: 180
Study 788993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 229
Study 788993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1200 mg
Number of subjects: 229
Study 788993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 229
Study 788993 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 229
Study 788993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 30734629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl-soaked Merocel® packing (50 mcg)
Number of subjects: 65
Study 30734629 — intervention group
Group type: COMPARATOR
Intervention: Saline-soaked packing
Number of subjects: 65
Study 28124405 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 90
Study 28124405 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no educational video)
Number of subjects: 90
Study 25246602 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 3
Study 25246602 — intervention group
Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 3
Study 25246602 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 3
Study 22813235 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 50 mg/day
Number of subjects: 157
Study 22813235 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV 150 mg/day
Number of subjects: 157
Study 22813235 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 21950702 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of Avastin
Number of subjects: 48
Study 21950702 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg Macugen
Number of subjects: 48
Study 21950702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (1 mg Avastin followed by 0.3 mg Macugen)
Number of subjects: 48
Study 18440952 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine-midazolam-propofol (KMP)
Number of subjects: 209
Study 18440952 — intervention group
Group type: COMPARATOR
Intervention: sufentanil-midazolam-propofol (SMP)
Number of subjects: 209
Study 16571390 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback
Number of subjects: 18
Study 16571390 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback
Number of subjects: 18
Study 12436326 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine test
Number of subjects: 29
Study 12436326 — intervention group
Group type: COMPARATOR
Intervention: Sympathetic nerve blockade
Number of subjects: 29
Study 10600092 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐1 0.01 mg/kg/hour and daily subcutaneous doses of rhGH 0.05 mg/kg/day
Number of subjects: 23
Study 10600092 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 23
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol, 1.3 mg/kg
Number of subjects: 18
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol, 4.4 mg/kg
Number of subjects: 18
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol, 0.13 mg/kg
Number of subjects: 18
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol, 0.44 mg/kg
Number of subjects: 18
Study 7864425 — intervention group
Group type: COMPARATOR
Intervention: no drug
Number of subjects: 18
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 18
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol
Number of subjects: 18
Study 7864425 — intervention group
Group type: EXPERIMENTAL
Intervention: esmolol and labetalol
Number of subjects: 18
Study 2167806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid (10%) and heparin (Lipid)
Number of subjects: 8
Study 2167806 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8
Study 6796270 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordesmethyldiazepam 2 mg (CDDZ2)
Number of subjects: 0
Study 6796270 — intervention group
Group type: COMPARATOR
Intervention: Chlordesmethyldiazepam 1 mg (CDDZ1)
Number of subjects: 0
Study 6796270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30441483 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-Trees algorithm for supervised classification
Number of subjects: 9
Study 30441483 — intervention group
Group type: EXPERIMENTAL
Intervention: Error Correcting Output Codes (ECOC) approach
Number of subjects: 9
Study 28062091 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred care intervention group
Number of subjects: 199
Study 28062091 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 199
Study 26670971 — intervention group
Group type: EXPERIMENTAL
Intervention: TTFields plus temozolomide
Number of subjects: 695
Study 26670971 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide alone
Number of subjects: 695
Study 24176132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender dialogue groups added to group savings program
Number of subjects: 934
Study 24176132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender dialogue groups added to group savings program (high adherence)
Number of subjects: 934
Study 24176132 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender dialogue groups added to group savings program (low adherence)
Number of subjects: 934
Study 24176132 — intervention group
Group type: COMPARATOR
Intervention: Group savings only (control)
Number of subjects: 934
Study 20857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 12
Study 20857093 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 12
Study 20857093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24692816 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/d)
Number of subjects: 20
Study 24692816 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8-12 mg/d)
Number of subjects: 20
Study 16793604 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.25 mg/kg bolus followed by 0.5 mg.kg(‐1).h(‐1) infusion)
Number of subjects: 20
Study 16793604 — intervention group
Group type: COMPARATOR
Intervention: Control (saline of the same amount)
Number of subjects: 20
Study 12658084 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical azelastine 0.02%
Number of subjects: 63
Study 12658084 — intervention group
Group type: COMPARATOR
Intervention: Topical mitomycin C (0.2 mg/10 mL)
Number of subjects: 63
Study 10726221 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder sticker and patient education sign in each examining room
Number of subjects: 778
Study 10726221 — intervention group
Group type: COMPARATOR
Intervention: Patient education sign only
Number of subjects: 778
Study 10726221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 778
Study 9143790 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure screening intervention
Number of subjects: 6000
Study 9143790 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy
Number of subjects: 6000
Study 9143790 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after withdrawal from therapy
Number of subjects: 6000
Study 9143790 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization to screening
Number of subjects: 6000
Study 7515115 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 116
Study 7515115 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 116
Study 7515115 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran
Number of subjects: 116
Study 7515115 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 116
Study 7515115 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 116
Study 7515115 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression stockings
Number of subjects: 116
Study 7515115 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 2954024 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fenoterol alone
Number of subjects: 94
Study 2954024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus ipratropium bromide
Number of subjects: 94
Study 2954024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol plus corticosteroids
Number of subjects: 94
Study 2954024 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 94
Study 29265884 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect exergames played twice weekly for 8 weeks
Number of subjects: 65
Study 29265884 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 65
Study 27582297 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise training (PRET)
Number of subjects: 48
Study 27582297 — intervention group
Group type: COMPARATOR
Intervention: Nonprogressive exercise intervention, modified Fitness Counts (mFC)
Number of subjects: 48
Study 23809507 — intervention group
Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 1093
Study 23809507 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG)
Number of subjects: 1093
Study 23809507 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance (IGT) without IFG
Number of subjects: 1093
Study 23809507 — intervention group
Group type: EXPERIMENTAL
Intervention: IGT and IFG
Number of subjects: 1093
Study 23809507 — intervention group
Group type: EXPERIMENTAL
Intervention: Indeterminate glucose tolerance (INDET)
Number of subjects: 1093
Study 23473266 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 94
Study 23473266 — intervention group
Group type: COMPARATOR
Intervention: Traditional open reduction and internal fixation (ORIF)
Number of subjects: 94
Study 20711070 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 960
Study 20711070 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine and silver sulfadiazine
Number of subjects: 960
Study 18190664 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment
Number of subjects: 405
Study 18190664 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance treatment
Number of subjects: 405
Study 18190664 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid treatment exposure longer than 7 days
Number of subjects: 405
Study 18190664 — intervention group
Group type: EXPERIMENTAL
Intervention: Older participants randomized to buprenorphine treatment
Number of subjects: 405
Study 18190664 — intervention group
Group type: EXPERIMENTAL
Intervention: Aboriginal or Torres Strait Islander participants
Number of subjects: 405
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron (A-131)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron (Electrolytic)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonyl iron (Ferronyl)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: H-reduced iron (AC-325)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: H-reduced iron (Hi-Sol)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonyl iron (CF)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced iron (Atomet 95SP)
Number of subjects: 48
Study 15864409 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (FeSO4)
Number of subjects: 48
Study 15864409 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron with 50 mg ascorbic acid (AA)
Number of subjects: 48
Study 12039500 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer septal occluder (ASO) for device closure
Number of subjects: 596
Study 12039500 — intervention group
Group type: COMPARATOR
Intervention: Surgical closure
Number of subjects: 596
Study 9808595 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg/d
Number of subjects: 372
Study 9808595 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 372
Study 7498447 — intervention group
Group type: COMPARATOR
Intervention: Tamm-Horsfall glycoproteins from healthy probands
Number of subjects: 2
Study 7498447 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamm-Horsfall glycoproteins from recurrent calcium oxalate renal stone formers
Number of subjects: 2
Study 2566048 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporin 10 mg/kg per day
Number of subjects: 0
Study 2566048 — intervention group
Group type: COMPARATOR
Intervention: Colchicine 1 mg orally per day
Number of subjects: 0
Study 794686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibezonium iodide tablets
Number of subjects: 160
Study 794686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibezonium iodide bubble-gums
Number of subjects: 160
Study 6111742 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic drugs
Number of subjects: 70
Study 6111742 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 70
Study 30732506 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (KREMEZIN®)
Number of subjects: 0
Study 28651370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle change with goals of weight reduction and 150 min/wk of moderate intensity exercise
Number of subjects: 555
Study 28651370 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin administered 850 mg twice a day
Number of subjects: 555
Study 28651370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study 27737719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) alone
Number of subjects: 250
Study 27737719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) with educational outreach
Number of subjects: 250
Study 27737719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) with shared learning opportunities
Number of subjects: 250
Study 27737719 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Facilitation (PF) with both educational outreach and shared learning opportunities
Number of subjects: 250
Study 24650695 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Hepatectomy (PH)
Number of subjects: 173
Study 24650695 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization (TACE)
Number of subjects: 173
Study 22007645 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum aldosterone
Number of subjects: 344
Study 20079208 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐DXM + RM group (40 mg/d of dexamethasone in a 4‐day pulse every 14 days for 3 cycles + 0.035 mg x kg(‐1) x d(‐1) for maintenance)
Number of subjects: 45
Study 20079208 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐DXM + SM group (40 mg/d of dexamethasone in a 4‐day pulse every 14 days for 3 cycles + 0.035 mg x kg(‐1) x d(‐1) only when platelet count < 20 x 10(9)/L)
Number of subjects: 45
Study 20079208 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine dosage of prednisone)
Number of subjects: 45
Study 20079208 — intervention group
Group type: EXPERIMENTAL
Intervention: HD‐DXM + RM group
Number of subjects: 45
Study 20079208 — intervention group
Group type: COMPARATOR
Intervention: HD‐DXM + SM group and Control group
Number of subjects: 45
Study 17207801 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted hatching
Number of subjects: 159
Study 17207801 — intervention group
Group type: COMPARATOR
Intervention: Hatching with acidified medium
Number of subjects: 159
Study 17207801 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5 transfers
Number of subjects: 159
Study 15080375 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml/kg of alcohol for 7 days
Number of subjects: 14
Study 15080375 — intervention group
Group type: COMPARATOR
Intervention: Control drink for 3 days
Number of subjects: 14
Study 15080375 — intervention group
Group type: COMPARATOR
Intervention: Alcohol restriction for 1 week
Number of subjects: 14
Study 11993223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-thoracolaparotomy
Number of subjects: 30
Study 11993223 — intervention group
Group type: COMPARATOR
Intervention: Conventional thoracolaparotomy
Number of subjects: 30
Study 9617979 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 25
Study 9617979 — intervention group
Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 25
Study 7799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography in women aged 50 to 74 years
Number of subjects: 13
Study 7799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography in women aged 40 to 49 years
Number of subjects: 13
Study 7799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-view mammography in women aged 40 to 49 years
Number of subjects: 13
Study 7799496 — intervention group
Group type: EXPERIMENTAL
Intervention: One-view mammography in women aged 40 to 49 years
Number of subjects: 13
Study 7799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with 7 to 9 years of follow-up in women aged 40 to 49 years
Number of subjects: 13
Study 7799496 — intervention group
Group type: EXPERIMENTAL
Intervention: Studies with 10 to 12 years of follow-up in women aged 40 to 49 years
Number of subjects: 13
Study 2649121 — intervention group
Group type: EXPERIMENTAL
Intervention: Exeter cement gun
Number of subjects: 21
Study 2649121 — intervention group
Group type: COMPARATOR
Intervention: Hand insertion of cement
Number of subjects: 21
Study 55895 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (400 mg daily) for 1 week before and 1 week after 5 mCi therapy dose of 131I
Number of subjects: 16
Study 55895 — intervention group
Group type: COMPARATOR
Intervention: 5 mCi of 131I without lithium therapy
Number of subjects: 16
Study 31662352 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE training intervention (1-day training session on patient-centred communication)
Number of subjects: 48
Study 31662352 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual consultations without ICE training)
Number of subjects: 48
Study 29156912 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic dexamethasone
Number of subjects: 81
Study 29156912 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic dexamethasone (Control)
Number of subjects: 81
Study 29156912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patient group
Number of subjects: 81
Study 29156912 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model for pain flare
Number of subjects: 81
Study 29156912 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable model for dexamethasone response
Number of subjects: 81
Study 25664999 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-nutrient supplement (550 mg DHA, 550 mg EPA, 10 µg vitamin D3 and 8 g whey protein)
Number of subjects: 42
Study 25664999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 25416084 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to participate in RCTs
Number of subjects: 1820
Study 25416084 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative impact of weight on life
Number of subjects: 1820
Study 25416084 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling unsatisfied/very unsatisfied with weight loss ability
Number of subjects: 1820
Study 25416084 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of weight control vs diabetes control
Number of subjects: 1820